A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB)

Using improved mouse models for gastric cancer, A*STAR scientists uncover a pool of cancer stem cells key to disease progression.

Ushering in an era of targeted precision medicine, scientists across A*STAR are propelling the research, commercialisation and implementation of RNA-based therapeutics.

Delving deep into the fundamentals of development and the frontiers of disease therapeutics, Mei Sheng Lau unravels the roles chromatin plays in gene regulation.

A*STAR researchers challenge existing theories around intestinal stem cell biology using a newly developed animal model of intestinal regeneration.

New data suggest that metformin administered to pregnant mothers may have unintended effects on the fetus, prompting the need for further assessment of the drug’s risk-benefit ratio.

Metabolic changes in the neurons of patients with amyotrophic lateral sclerosis may be reversed with vitamin B3 supplements.

A breakthrough stem cell transplant technology uses donated cadaver eyes to restore vision in patients with retinal degeneration.

From the public sector to innovative startups and industry giants, A*STAR scholars are blazing the trail across Singapore’s research ecosystem.

Researchers engineer specialized T cells that can transiently and effectively attack liver cancer cells even in the presence of immunosuppressive drugs.

From music streaming technology to COVID-19 tests, A*STAR Assistant Chief Executive (Enterprise) Sze Wee Tan details how the agency is bringing their innovations out of the lab and into the real world.

Through the years, A*STAR has always stood at the forefront of science and technology and innovation. Here’s how A*STAR came to be and what it has in store in the upcoming decades.

Broad-acting antibiotics can disrupt the gut microbiome and create the perfect conditions for potentially life-threatening yeast infections to flourish.